EUVIMEDEUVIMED entdecken
LeserbriefOpen Access · CC BY 4.0

Polymorphism engineering of mefenamic acid for enhanced pharmacokinetic performance

Parteek Prasher, Mousmee Sharma

EXCLI Journal · 17.03.2026 · 25 · 390-395

DOI: 10.17179/excli2026-9258 ↗

Kurz gefasst

Leserbrief in der Zeitschrift EXCLI Journal, online erschienen am 17.03.2026. Verfasst von Parteek Prasher und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Chemistry, University of Petroleum & Energy Studies (UPES), Dehradun, 248007, India. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Mefenamic acid, a BCS Class II drug, continues to face the longstanding challenges related to its suboptimal solubility and variable absorption, which necessitates frequent dosing of the drug resulting in ulcerogenicity. Guided by its polymorphic forms, the co-crystallization of mefenamic acid offers a unique advantage over the other advanced formulation strategies, including hydrotropy, nanosizing, and complexation for improving the drug bioavailability. However, the contemporary research limited only to the proof-of-concept studies fails to provide a clinical evidence or translational insights, which necessitates the rational design of synthons and engineering of the solid-state landscape of the drug for developing the co-crystallization formulation of mefenamic acid. This commentary provides critical insights into the polymorphism-driven co-crystal design of mefenamic acid aimed at filling the critical gaps in scalability and clinical translation.

Autor:innen und Institutionen

  • Department of Chemistry, University of Petroleum & Energy Studies (UPES), Dehradun, 248007, India.
  • Department of Chemistry, Uttaranchal University, Dehradun, 248007, India.

Zitieren

APA

Prasher, P., & Sharma, M. (2026). Polymorphism engineering of mefenamic acid for enhanced pharmacokinetic performance. EXCLI Journal, 25, 390-395. https://doi.org/10.17179/excli2026-9258

Vancouver

Prasher P, Sharma M. Polymorphism engineering of mefenamic acid for enhanced pharmacokinetic performance. EXCLI Journal. 2026;25:390-395. doi:10.17179/excli2026-9258

BibTeX
@article{Prasher2026,
  author = {Prasher, Parteek and Sharma, Mousmee},
  title = {Polymorphism engineering of mefenamic acid for enhanced pharmacokinetic performance},
  journal = {EXCLI Journal},
  year = {2026},
  volume = {25},
  pages = {390--395},
  doi = {10.17179/excli2026-9258}
}
Kostenlos starten →